183 related articles for article (PubMed ID: 19050307)
1. Splenic plasma cells can serve as a source of amyloidogenic light chains.
Solomon A; Macy SD; Wooliver C; Weiss DT; Westermark P
Blood; 2009 Feb; 113(7):1501-3. PubMed ID: 19050307
[TBL] [Abstract][Full Text] [Related]
2. Binding of nascent collagen by amyloidogenic light chains and amyloid fibrillogenesis in monolayers of human fibrocytes.
Harris DL; King E; Ramsland PA; Edmundson AB
J Mol Recognit; 2000; 13(4):198-212. PubMed ID: 10931557
[TBL] [Abstract][Full Text] [Related]
3. Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensity.
Martin EB; Williams A; Wooliver C; Heidel RE; Adams S; Dunlap J; Ramirez-Alvarado M; Blancas-Mejia LM; Lands RH; Kennel SJ; Wall JS
PLoS One; 2017; 12(3):e0174152. PubMed ID: 28350808
[TBL] [Abstract][Full Text] [Related]
4. Amyloidomas of the nervous system: a monoclonal B-cell disorder with monotypic amyloid light chain lambda amyloid production.
Laeng RH; Altermatt HJ; Scheithauer BW; Zimmermann DR
Cancer; 1998 Jan; 82(2):362-74. PubMed ID: 9445195
[TBL] [Abstract][Full Text] [Related]
5. Systemic Amyloidosis Due to Clonal Plasma Cell Diseases.
Bianchi G; Kumar S
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1009-1026. PubMed ID: 33099420
[TBL] [Abstract][Full Text] [Related]
6. Deposition of kappa and lambda light chains in amyloid filaments of dialysis-related amyloidosis.
Brancaccio D; Ghiggeri GM; Braidotti P; Garberi A; Gallieni M; Bellotti V; Zoni U; Gusmano R; Coggi G
J Am Soc Nephrol; 1995 Oct; 6(4):1262-70. PubMed ID: 8589295
[TBL] [Abstract][Full Text] [Related]
7. Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis.
Weiss BM; Wong SW; Comenzo RL
Blood; 2016 May; 127(19):2275-80. PubMed ID: 26907632
[TBL] [Abstract][Full Text] [Related]
8. Production and immunodiagnostic applications of antihuman light chain monoclonal antibodies.
Abe M; Goto T; Kennel SJ; Wolfenbarger D; Macy SD; Weiss DT; Solomon A
Am J Clin Pathol; 1993 Jul; 100(1):67-74. PubMed ID: 7688492
[TBL] [Abstract][Full Text] [Related]
9. Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis.
Poshusta TL; Sikkink LA; Leung N; Clark RJ; Dispenzieri A; Ramirez-Alvarado M
PLoS One; 2009; 4(4):e5169. PubMed ID: 19365555
[TBL] [Abstract][Full Text] [Related]
10. Amyloid formation in light chain amyloidosis.
Ramirez-Alvarado M
Curr Top Med Chem; 2012; 12(22):2523-33. PubMed ID: 23339305
[TBL] [Abstract][Full Text] [Related]
11. Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment.
Perfetti V; Casarini S; Palladini G; Vignarelli MC; Klersy C; Diegoli M; Ascari E; Merlini G
Blood; 2002 Aug; 100(3):948-53. PubMed ID: 12130507
[TBL] [Abstract][Full Text] [Related]
12. Amyloidogenic light chains impair plasma cell survival.
Pick M; Lebel E; Elgavish S; Benyamini H; Nevo Y; Hertz R; Bar-Tana J; Rognoni P; Merlini G; Gatt ME
Haematologica; 2023 Dec; 108(12):3359-3371. PubMed ID: 37381778
[TBL] [Abstract][Full Text] [Related]
13. Review: immunoglobulin light chain amyloidosis--the archetype of structural and pathogenic variability.
Bellotti V; Mangione P; Merlini G
J Struct Biol; 2000 Jun; 130(2-3):280-9. PubMed ID: 10940232
[TBL] [Abstract][Full Text] [Related]
14. Analysis of plasma cell clonality in localized AL amyloidosis.
Setoguchi M; Hoshii Y; Kawano H; Ishihara T
Amyloid; 2000 Mar; 7(1):41-5. PubMed ID: 10842704
[TBL] [Abstract][Full Text] [Related]
15. Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis.
Lisenko K; Schönland SO; Jauch A; Andrulis M; Röcken C; Ho AD; Goldschmidt H; Hegenbart U; Hundemer M
Cancer Med; 2016 Jul; 5(7):1464-72. PubMed ID: 27109862
[TBL] [Abstract][Full Text] [Related]
16. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden.
Comenzo RL; Zhang Y; Martinez C; Osman K; Herrera GA
Blood; 2001 Aug; 98(3):714-20. PubMed ID: 11468171
[TBL] [Abstract][Full Text] [Related]
17. Immunoglobulin light chain, Blimp-1 and cytochrome P4501B1 peptides as potential vaccines for AL amyloidosis.
Flies A; Ahmadi T; Parks AJ; Prokaeva T; Weng L; Rolfe SS; Seldin DC; Sherr DH
Immunol Cell Biol; 2012 May; 90(5):528-39. PubMed ID: 21894172
[TBL] [Abstract][Full Text] [Related]
18. Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation.
Kazman P; Vielberg MT; Pulido Cendales MD; Hunziger L; Weber B; Hegenbart U; Zacharias M; Köhler R; Schönland S; Groll M; Buchner J
Elife; 2020 Mar; 9():. PubMed ID: 32151314
[TBL] [Abstract][Full Text] [Related]
19. [Detection of monoclonal plasma cells in bone marrow and spleen of primary amyloidosis].
Katayama Y; Sakai A; Nobuyoshi M; Shimomura T; Kimura A
Rinsho Ketsueki; 2001 Sep; 42(9):705-9. PubMed ID: 11680983
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the management of AL Amyloidosis.
Kastritis E; Dimopoulos MA
Br J Haematol; 2016 Jan; 172(2):170-86. PubMed ID: 26491974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
